CD19 and leukemia: While CD19-targeting CAR-T products have earned FDA approval for treating B-cell lymphoma and leukemia, they carry risks, like CRS, neurotoxicity, and B-cell aplasia, primarily due to on-target off-tumor toxicities (152, 153).